Novitero

Company Overview

Snapshot

Founded in February 2014 by Itzchak Angel, PhD, Novitero operated with 1–10 employees. The company raised $50,000 across one funding round. The company ceased operations in January 2021.

Business overview

Novitero is a computational drug design and development company focused on creating precise and effective cancer treatments. The company's technology is designed to proactively combat cancer by anticipating its mutational activities and overcoming resistance to therapies. Novitero utilizes computational methods to predict mutational fingerprints implicated in drug resistance to various therapeutic targets, subsequently designing, validating, and out-licensing new drugs that bypass these mutations. It operates within the Health Tech & Life Sciences sector, specifically in Pharma & Medical Biotechnology and Drugs Discovery & Development, targeting the Pharmaceuticals and Biotechnology markets.

Company Intelligence Q&A

What is Novitero's primary focus?

Novitero specializes in computational drug design and development, aiming to create precise and effective cancer treatments by anticipating and overcoming drug resistance mutations.

When was Novitero founded?

Novitero was founded in February 2014.

Who founded Novitero?

Novitero was founded by Itzchak Angel, PhD.

What is the status of Novitero?

Novitero is currently non-active, having ceased operations in January 2021.

What was Novitero's total disclosed funding?

Novitero raised a total of $50,000 in a single Pre-Funding round.